<DOC>
	<DOCNO>NCT00543075</DOCNO>
	<brief_summary>To characterize pharmacokinetics G3139 subject normal , mildly impaired , moderately impaired renal function receive Genasense 3 mg/kg/day continuous intravenous infusion 2 day ( 48 hour ) .</brief_summary>
	<brief_title>Pharmacokinetic Study Genasense Subjects With Normal Renal Function , Mildly Impaired Renal Function , Moderately Impaired Renal Function</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Key inclusion criterion : Age &gt; 18 year Adequate organ function determine &lt; 7 day prior start study medication ( except renal function , specify per protocol ) Creatinine clearance &gt; 80 mL/min base CockcroftGault formula subject Group 1 ; 50 less equal 80 mL/min base CockcroftGault formula confirm base measure creatinine clearance subject Group 2 ; 30 49 mL/min base CockcroftGault formula confirm base measure creatinine clearance subject Group 3 Key exclusion criterion : Significant medical disease Prior organ allograft Coexisting condition would require subject continue therapy treatment ( infusion ) phase study drug know alter renal function</criteria>
	<gender>All</gender>
	<minimum_age>18 Weeks</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>Renal Function</keyword>
	<keyword>Adult</keyword>
	<keyword>Genasense</keyword>
	<keyword>oblimersen</keyword>
	<keyword>G3139</keyword>
	<keyword>Genta</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>